Pseudomonas Vaccine News

[Guest guest]

FEMS Immunology and Medical Microbiology, Vol. 37 (2-3) (2003) pp.

147-153

DNA vaccines against chronic lung infections by Pseudomonas aeruginosa

J. Staczek * jstacz@... , L.B. Gilleland, H.C. van der Heyde and

H.E. Gilleland Jr.

Department of Microbiology and Immunology, Louisiana State University

Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932,

USA

Abstract

Vaccines containing outer membrane protein F (OprF) of Pseudomonas

aeruginosa are effective in reducing lesion severity in a mouse

pulmonary chronic infection model. One OprF-based vaccine, called F/I,

contains carboxy oprF sequences fused to oprI in an expression vector.

When delivered three times biolistically by gene gun, the F/I vaccine

induces protection that is antibody-mediated in outbred mice. To

demonstrate the role of F/I-induced antibody-mediated immunity,

B-cell-deficient [b()] and B-cell-intact [b(+)] mice were immunized with

F/I, challenged with Pseudomonas, and examined for lesion severity. As

expected, F/I-immunized B(+) mice had fewer and less severe lesions than

vector-immunized B(+) mice. However, surprisingly, F/I- and

vector-immunized B() mice were equally protected to levels similar to

F/I-immunized B(+) mice. Examination of immune cell populations and

cytokine levels indicated a relative increase in the quantity of CD3+

T-lymphocytes in vector- or F/I-immunized and challenged B() mice

compared to B(+) mice. These data indicate the protective role played by

cell-mediated immunity in B() mice, which supports our hypothesis that

cell-mediated immunity can play an important role in protection against

P. aeruginosa.

Becki

YOUR FAVORITE LilGooberGirl

YOUNGLUNG EMAIL SUPPORT LIST

www.topica.com/lists/younglung

Pediatric Interstitial Lung Disease Society

http://groups.yahoo.com/group/InterstitialLung_Kids/